{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:18:56Z","timestamp":1792192736990,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[1999,10]]},"DOI":"10.1053\/hj.1999.v138.a100461","type":"journal-article","created":{"date-parts":[[2004,7,28]],"date-time":"2004-07-28T10:40:39Z","timestamp":1091011239000},"page":"S287-S296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"S","title":["Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors"],"prefix":"10.1053","volume":"138","author":[{"given":"James C.","family":"Blankenship","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/hj.1999.v138.a100461_BIB1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100461_BIB2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study","volume":"349","author":"CAPTURE Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.a100461_BIB3","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100461_BIB4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.a100461_BIB5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II","volume":"349","author":"IMPACT-II Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/hj.1999.v138.a100461_BIB6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100461_BIB7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","author":"RESTORE Investigators","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100461_BIB8","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100461_BIB9","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non\u2013Q-wave myocardial infarction","volume":"338","author":"Platelet Receptor","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100461_BIB10","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","article-title":"International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina","volume":"97","author":"PARAGON Investigators","year":"1998","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100461_BIB11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.94.5.899","article-title":"Platelet membrane receptor glycoprotein IIb\/IIIa antagonism in unstable angina: Canadian lamifiban study","volume":"94","author":"Theroux","year":"1996","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100461_BIB12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial-Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"GUSTO Investigators","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/hj.1999.v138.a100461_BIB14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0002-9343(87)90004-0","article-title":"Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy","volume":"82","author":"Landefeld","year":"1987","journal-title":"Am J Med"},{"key":"10.1053\/hj.1999.v138.a100461_BIB15","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1161\/01.CIR.91.8.2151","article-title":"Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb\/IIIa blocker integrelin in elective coronary intervention","volume":"91","author":"Tcheng","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100461_BIB16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.7326\/0003-4819-116-5-403","article-title":"Practice strategies for elective red cell transfusion","volume":"116","author":"American College of Physicians","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1053\/hj.1999.v138.a100461_BIB17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9149(97)00796-0","article-title":"Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for Prevention of Ischemic Complications (EPIC) trial","volume":"81","author":"Blankenship","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB18","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0735-1097(98)00130-2","article-title":"Modifiable risk factors for vascular access site complications of angioplasty with glycoprotein IIb\/IIIa receptor inhibition in the IMPACT II trial","volume":"31","author":"Mandak","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.CIR.94.4.629","article-title":"Economic assessment of platelet glycoprotein inhibition for prevention of ischemic complications of high-risk coronary angioplasty","volume":"94","author":"Mark","year":"1996","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100461_BIB20","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1161\/01.CIR.90.4.1757","article-title":"Pharmacodynamics of chimeric glycoprotein IIb\/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty","volume":"90","author":"Tcheng","year":"1994","journal-title":"Circulation"},{"issue":"suppl 4A","key":"10.1053\/hj.1999.v138.a100461_BIB21","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/S0002-9149(97)00572-9","article-title":"Clinical pharmacology of eptifibatide","volume":"80","author":"Phillips","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0002-9149(96)00582-6","article-title":"Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion","volume":"78","author":"Kereiakes","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0002-9149(96)00749-7","article-title":"Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb\/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization","volume":"79","author":"Lincoff","year":"1997","journal-title":"Am J Cardiol"},{"issue":"suppl I","key":"10.1053\/hj.1999.v138.a100461_BIB24","first-page":"I","article-title":"Decreased vascular access site bleeding after coronary intervention with abciximab in the EPILOG vs the EPIC trial","volume":"96","author":"Blankenship","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100461_BIB25","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1161\/01.CIR.91.12.2882","article-title":"Bleeding complications with the chimeric antibody to platelet glycoprotein IIb\/IIIa integrin in patients undergoing percutaneous coronary intervention","volume":"91","author":"Aguirre","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/hj.1999.v138.a100461_BIB26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0002-8703(95)90305-4","article-title":"Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents","volume":"130","author":"Tcheng","year":"1995","journal-title":"Am Heart J"},{"key":"10.1053\/hj.1999.v138.a100461_BIB27","first-page":"73A","article-title":"Elimination of excess vascular access site bleeding during coronary intervention with abciximab","volume":"33","author":"Blankenship","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB28","first-page":"41A","article-title":"Incidence of intra-cranial hemorrhage in trials of glycoprotein IIb\/IIIa receptor inhibitor drugs","volume":"33","author":"Blankenship","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB29","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/0002-9149(94)90474-X","article-title":"Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery","volume":"74","author":"Boehrer","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0002-9149(97)00286-5","article-title":"Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving Abciximab","volume":"80","author":"Juergens","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB31","first-page":"292","article-title":"Abciximab and the risk of bleeding during emergency cardiac operations","volume":"67","author":"Arjomand","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/hj.1999.v138.a100461_BIB32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0003-4975(97)01299-X","article-title":"Abciximab and excessive bleeding in patients undergoing emergency cardiac operations","volume":"65","author":"Gammie","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/hj.1999.v138.a100461_BIB33","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0022-5223(98)70296-X","article-title":"Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab","volume":"115","author":"Alvarez","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"suppl A","key":"10.1053\/hj.1999.v138.a100461_BIB34","first-page":"38A","article-title":"Care of the patient receiving ReoPro following angioplasty","volume":"6","author":"Brezina","year":"1994","journal-title":"J Invas Cardiol"},{"issue":"suppl A","key":"10.1053\/hj.1999.v138.a100461_BIB35","first-page":"34A","article-title":"Post-procedural patient management: prevention and management of bleeding complications","volume":"6","author":"Aguirre","year":"1994","journal-title":"J Invas Cardiol"},{"key":"10.1053\/hj.1999.v138.a100461_BIB36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0002-9149(97)00437-2","article-title":"Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention","volume":"80","author":"Kereiakes","year":"1997","journal-title":"Am J Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870399004500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870399004500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:03:33Z","timestamp":1757567013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870399004500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["S0002870399004500"],"URL":"https:\/\/doi.org\/10.1053\/hj.1999.v138.a100461","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[1999,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/hj.1999.v138.a100461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}